Regeneron Pharmaceuticals Inc Asset Resilience Ratio
Regeneron Pharmaceuticals Inc asset resilience ratio. Regeneron Pharmaceuticals Inc (REGN) has an Asset Resilience Ratio of 13.27% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Regeneron Pharmaceuticals Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Regeneron Pharmaceuticals Inc (1999–2025)
Asset resilience ratio of Regeneron Pharmaceuticals Inc from 1999 to 2025. This chart shows how Regeneron Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See REGN cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Regeneron Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see REGN total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $5.54 Billion | 13.27% |
| Total Liquid Assets | $5.54 Billion | 13.27% |
Asset Resilience Insights
- Moderate Liquidity: Regeneron Pharmaceuticals Inc has 13.27% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Regeneron Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Regeneron Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Regeneron Pharmaceuticals Inc Asset Resilience Ratio by Year (1999–2025)
Regeneron Pharmaceuticals Inc asset resilience ratio by year from 1999 to 2025. The table below shows the annual Asset Resilience Ratio data for Regeneron Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 13.53% | $5.49 Billion | $40.56 Billion | -3.75pp |
| 2024-12-31 | 17.28% | $6.52 Billion | $37.76 Billion | -7.25pp |
| 2023-12-31 | 24.53% | $8.11 Billion | $33.08 Billion | +8.66pp |
| 2022-12-31 | 15.87% | $4.64 Billion | $29.21 Billion | +4.83pp |
| 2021-12-31 | 11.04% | $2.81 Billion | $25.43 Billion | +2.93pp |
| 2020-12-31 | 8.12% | $1.39 Billion | $17.16 Billion | -2.67pp |
| 2019-12-31 | 10.78% | $1.60 Billion | $14.81 Billion | -0.65pp |
| 2018-12-31 | 11.44% | $1.34 Billion | $11.73 Billion | +4.63pp |
| 2017-12-31 | 6.81% | $596.85 Million | $8.76 Billion | -0.41pp |
| 2016-12-31 | 7.22% | $503.48 Million | $6.97 Billion | +3.01pp |
| 2015-12-31 | 4.21% | $236.12 Million | $5.61 Billion | -2.29pp |
| 2014-12-31 | 6.50% | $251.76 Million | $3.87 Billion | +1.14pp |
| 2013-12-31 | 5.37% | $158.38 Million | $2.95 Billion | +1.63pp |
| 2012-12-31 | 3.74% | $77.82 Million | $2.08 Billion | +0.47pp |
| 2011-12-31 | 3.27% | $43.33 Million | $1.32 Billion | -9.28pp |
| 2010-12-31 | 12.56% | $136.80 Million | $1.09 Billion | -5.56pp |
| 2009-12-31 | 18.11% | $134.25 Million | $741.20 Million | -15.76pp |
| 2008-12-31 | 33.87% | $226.95 Million | $670.04 Million | +5.30pp |
| 2007-12-31 | 28.57% | $267.53 Million | $936.26 Million | -9.27pp |
| 2006-12-31 | 37.84% | $221.40 Million | $585.09 Million | +10.91pp |
| 2005-12-31 | 26.93% | $114.04 Million | $423.50 Million | -14.24pp |
| 2004-12-31 | 41.16% | $194.75 Million | $473.11 Million | +4.57pp |
| 2003-12-31 | 36.59% | $175.49 Million | $479.56 Million | -10.45pp |
| 2002-12-31 | 47.04% | $184.19 Million | $391.57 Million | +19.25pp |
| 2001-12-31 | 27.79% | $137.69 Million | $495.40 Million | -13.80pp |
| 2000-12-31 | 41.60% | $86.63 Million | $208.27 Million | +10.57pp |
| 1999-12-31 | 31.02% | $42.50 Million | $137.00 Million | -- |
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degenera… Read more